Associate Professor
Andrew Chang

MBBS(Hons), PhD (Syd), FRANZCO, FRACS
Read below
  • Background
  • Publications
  • Associate Professor Andrew Chang is a vitreoretinal surgeon and ophthalmologist. He holds an academic appointment of Clinical Associate Professor at the University of Sydney. He is a consultant ophthalmologist and the Head of Ophthalmology and the Head of the Retinal Unit at the Sydney Eye Hospital. He is the Medical Director of Sydney Retina Clinic.

    He graduated from University of Sydney Medical School and trained at the Sydney Eye Hospital with fellowships at Royal Victorian Eye and Ear Hospital and in the United States. He was awarded a PhD for research into retinal and choroidal angiography performed in the Universities of California and Sydney.

    His commitment to international ophthalmology includes Secretary General of the Asia-Pacific Vitreoretinal Society (APVRS) and Council Member of the (Asia Pacific Academy of Ophthalmolog) APAO. He is a clinician advisor to the Department of Health Australia. He serves on the Boards of the RANZCO and the Sydney Eye Hospital Foundation. Professional awards include the Achievement Award and Distinguished Service Award of the APAO and the RANZCO Excellence in Teaching Award.

    Associate Professor Chang is enthusiastically involved in basic science and clinical trials research receiving research grant funding in Australia and USA. His research is extensively published in peer-reviewed scientific literature. He serves on the editorial boards of scientific peer-reviewed journals.

    In wider healthcare activities, Associate Professor Chang is engaged in the complexities of modern hospital healthcare delivery. He supports new medical drug and devices by engaging in clinical trials development. He is driving strategies aimed at better patient engagement with healthcare professionals using the latest in cloud, IoT and Artificial Intelligence.

    Professional History

    2020

    uamviboonsuk P, Lai T, Chang A, Lai C, Mieler W, Lam, Dennis SC ; for Asia-Pacific Vitreo-Retina Society Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19, Asia-Pacific Journal of Ophthalmology: March-April 2020 – Volume 9 – Issue 2 – p 85-87

    Spooner K, Fraser-Bell S, Hong T, Chang A. Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2020 Jan;9(1):48.

    Spooner K, Fraser‐Bell S, Hong T, Chang A. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long‐term treatment with bevacizumab or ranibizumab. Clinical & Experimental Ophthalmology. 2020 Jan;48(1):53-60.

    Tang YF, Chang A, Campbell WG, Connell PP, Hunyor AP, McAllister IL, Essex RW. Surgical management of traumatic macular hole: Optical coherence tomography features and outcomes. Retina. 2020 Feb 1;40(2):290-8.

    Broadhead GK, Hong T, Chang AA. To Treat or Not to Treat: Management Options for Symptomatic Vitreous Floaters. The Asia-Pacific Journal of Ophthalmology. 2020 Feb 24.

    Ong EL, Spooner K, Hong T, Chang A. Brolucizumab: An evolution in treatment for neovascular age-related macular degeneration. Expert Review of Ophthalmology. 2020 Mar 3 (Just accepted).

    Kunimoto D, Yoon YH, Wykoff CC, Chang A, Khurana RN, Maturi RK, Agostini H, Souied E, Chow DR, Lotery AJ, Ohji M. Efficacy and Safety of Abicipar in Neovascular Age‐Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. Ophthalmology. 2020 Apr 9.

    Spooner K, Fraser-Bell S, Hong T, Chang A. Optical Coherence Tomography angiography and ultrawide field angiography findings in eyes with refractory macular oedema secondary to retinal vein occlusion switched to aflibercept. A subanalysis from a 48 week prospective study. In Press April 2020.

    Spooner K, Fraser-Bell S, Hong T, Chang A. Patient reported outcomes from a phase IV study of aflibercept in patients with refractory retinal vein occlusions. In Press April 2020

    2019

    Spooner K, Fraser-Bell S, Hong T, Chang A. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis Ophthalmogica. 2019

    Spooner KL, Guinan G, Koller S, Hong T, Chang AA. Burden of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia. Diabetes Metab Syndr Obes. 2019 Sep 19;12:1913-1921.

    Spooner K, Fraser‐Bell S, Hong T, Chang A. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long‐term treatment with bevacizumab or ranibizumab. Clinical & Experimental Ophthalmology. 2019 Sep;48(1):53-60.

    Spooner K, Hong T, Fraser-Bell S, Chang A. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusions: A Systematic Review and Meta-Analysis. Asia Pac J Ophthalmol (Phila). 2019 May-Jun;8(3):236-246.

    Spooner K, Hong T, Bahrami B, Chang A. A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept. Acta Ophthalmol. 2019 Feb;97(1):15-23.

    Spooner K, Hong T, Nair R, Chow N, Broadhead G, Wijeyakumar W, Chang A. Long‐term outcomes of switching to aflibercept for treatment‐resistant neovascular age‐related macular degeneration. Acta ophthalmologica. 11 Feb 2019

    Broadhead G, Grigg J, McCluskey P, Hong T, Schlub T, Chang A. Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial. Graefe’s Archive for Clinical and Experimental Ophthalmology. 28 Jan 2019

    Spooner K, Fraser-Bell S, Hong T, Chang A. 5 year outcomes of retinal vein occlusion treated with vascular endothelial derived growth factor inhibitors. BMJ ophthal 2019

    Ho I, Fernandez G,  Levasseur S, Ting E, Liew G, Playfair J, Downie J, Gorbatov M, Hunyor A, Chang A. Early Pars plana vitrectomy for treatment of acute infective endophthalmitis. Asia Pacific Journal of Ophthalmology. 2019

    Spooner K, Hong T, Fraser-Bell S, Chang A. Current outcomes of Anti-VEGF therapy in the treatment of macular oedema secondary to branch retinal vein occlusions: A meta-analysis. Ophthalmologica 2019

    Wan R, Hong T, Tariq Y, Chang A. Pharmacotherapy of vitreomacular traction. Curr Pharm Des 2019

    Bahrami B, Hong T, Schlub T, Chang A. Aflibercept for persistent diabetic macular oedema: 48 week outcomes. Retina. 1 Jan 2019

    Bahrami B, Hong T, Peto T, Chang A. Ultra-Widefield Fluorescein Angiography as a Biomarker for Response to Switch in Therapy in Persistent DME. Ophthalmic Surgery, Lasers and Imaging Retina. 2019 Dec 27;50(12):771-8.

    Paul R, Simunovic M, Dawkins R, Bhullar G, Essex R, Chang A, Allen P. Early vitrectomy in endophthalmitis. In clinical and experimental ophthalmology 2019 Nov 1 (vol. 47, pp. 155-155). 111 river st, hoboken 07030-5774, nj usa: wiley.

    Ong E, Spooner K, Hong T, Chang A. Longitudinal retinal ganglion cell thickness change in patients receiving intravitreal anti-vascular endothelial growth factor for neovascular age-related macular degeneration. In Clinical And Experimental Ophthalmology 2019 Nov 1 (vol. 47, pp. 159-159). 111 river st, hoboken 07030-5774, nj usa: wiley.

    Spooner K, Fraser-Bell S, Cozzi M, Monteduro D, Luo K, Hong T, Munk M, Invernizzi A, Staurenghi G, Chang A. Comparison of macular atrophy in eyes with neovascular age-related macular degeneration treated with VEGF inhibitors using a treat-and-extend or pro re nata regimen: 4-year results of the MANEX study. In Clinical And Experimental Ophthalmology 2019 Nov 1 (Vol. 47, Pp. 63-63). 111 River St, Hoboken 07030-5774, Nj Usa: Wiley.

    Spooner K, Fraser-Bell S, Hong T, Chang A. Aflibercept In Macular Oedema Secondary To Retinal Vein Occlusion Refractory To Previous Bevacizumab Or Ranibizumab: 48 Week Outcomes. In Clinical And Experimental Ophthalmology 2019 Nov 1 (Vol. 47, Pp. 155-156). 111 River St, Hoboken 07030-5774, Nj Usa: Wiley.

    Hong T, Phan L, Spooner K, Chang A. Comparing Morphological Outcomes Between Ranibizumab And Afliberept For The Treatment Of Neovascular Age-Related Macular Degeneration. In Clinical And Experimental Ophthalmology 2019 Nov 1 (Vol. 47, Pp. 156-157). 111 River St, Hoboken 07030-5774, Nj Usa: Wiley.

    Bahrami B, Shen W, Zhu L, Zhang T, Chang A, Gillies MC. Effects of VEGF inhibitors on human retinal pigment epithelium under high glucose and hypoxia. Clinical & experimental ophthalmology. 2019 Nov;47(8):1074-81.

    Wan R, Chang A. Optic disc pit maculopathy: a review of diagnosis and treatment. Clinical and Experimental Optometry. 2019 Aug 22.

    Spooner K, Hong T, Nair R, Chow NC, Broadhead GK, Wijeyakumar W, Chang AA. Long‐term outcomes of switching to aflibercept for treatment‐resistant neovascular age‐related macular degeneration. Acta ophthalmologica. 2019 Aug;97(5):e706-12.

    Duerr ER, Chang A, Venkateswaran N, Goldhardt R, Levitt RC, Gregori NZ, Sarantopoulos CD, Galor A. Resolution of pain with periocular injections in a patient with a 7-year history of chronic ocular pain. American journal of ophthalmology case reports. 2019 Jun 1;14:35-8.

    Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ, Chang A, Syed A, Broadhead G, Pham T, Hong T. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 2019 May 1;126(5):723-34.

    Spooner K, Fraser-Bell S, Hong T, Chang AA. Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors. BMJ open ophthalmology. 2019 Mar 1;4(1):e000249.

    Spooner K, Hong T, Bahrami B, Chang A. A meta‐analysis of patients with treatment‐resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept. Acta ophthalmologica. 2019 Feb;97(1):15-23.

    Broadhead GK, Grigg JR, McCluskey P, Hong T, Schlub TE, Chang AA. Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2019 Jan 28;257(1):31-40.

    Ho IV, Fernandez-Sanz G, Levasseur S, Ting E, Liew G, Playfair J, Downie J, Gorbatov M, Hunyor AP, Chang AA. Early pars plana vitrectomy for treatment of acute infective endophthalmitis. The Asia-Pacific Journal of Ophthalmology. 2019 Jan 1;8(1):3-7.

    Bahrami B, Hong T, Schlub TE, Chang AA. Aflibercept For Persistent Diabetic Macular Edema: Forty-Eight–Week Outcomes. Retina. 2019 Jan 1;39(1):61-8.

    Ong AP, Angbue Te N, Zagora SL, Symes RJ, Yates W, Chang AA, McCluskey PJ, Simunovic MP. Post‐surgical versus post‐intravitreal injection endophthalmitis: changing patterns in causative flora. Clinical & experimental ophthalmology. 2019 Jan;47(1):57-62.

    2018

    Chow N, Hong T, Chang A. Multimodal imaging of macular subretinal deposits following intravitreal ocriplasmin injection. AJO Case Reports 2018 [Epub ahead of print]

    Spooner K, Bahrami B, Hong T, Chang A. A Meta-Analysis of Patients with Treatment Resistant Macular Oedema Secondary to Retinal Vein Occlusions following Switching to Aflibercept. Acta Ophthalmologica (Accepted for publication)

    Bahrami B, Hong T, Schlub T, Chang A. Aflibercept for persistent diabetic macular edema: 48 week outcomes. Retina. (in press)

    Ong PC, Te NA, Zagora S, Symes R, Yates Y, Chang A, McCluskey P, Simunovic M. Post-surgical versus post-intravitreal injection endophthalmitis: changing patterns in causative flora. Clinical & Experimental Ophthalmology (In press)

    2017

    Chang A, Chan P, Schlottman. Latest developments in age-related macular degeneration. Asia Pac J Ophthalmol. 2017 [Epub ahead of print]

    Bahrami B, Hong T, Gilles MC, Chang A. Anti-VEGF therapy for diabetic eye disease. Asia Pac J Ophthalmol (Phila). 2017 Oct 26. doi: 10.22608/APO.2017350. [Epub ahead of print]

    Broadhead G, Hong T, Grigg J, McCluskey P, Schlub T, Chang A. Choroidal Thickness and Microperimetry Sensitivity in Age-Related Macular Degeneration. Ophthalmic Research (Accepted for publication)

    Bahrami B, Hong T, Zhu M, Schlub T, Chang A. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. (Accepted for publication)

    Chew J, Zhu M, Broadhead G, Luo K, Hong T, Chang A. Bilateral neovascular age-related macular degeneration: Comparisons between first and second eyes. Ophthalmologica (Accepted for publication)

    Bahrami B, Ewe S, Hong T, Zhu M, Ong G, Luo K, Chang A. Influence of retinal pathology on the reliability of macular thickness measurement: a comparison between optical coherence tomography devices. Ophthalmic Surgery Laser and Imaging Retina. (Accepted for publication)

    Nair R, Chang A. Challenges in the treatment of age-related macular degeneration. Medicine Today. 2017, 18(2): 400-400

    Spooner K, Hong T, Wijeyakumar W, Chang AA. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis. Clinical Ophthalmology 2017, 11:161-177

    Bahrami B, Hong T, Zhu M, Schlub TE, Chang A. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1133-1140

    2016

    Zhu M, Wijeyakumar W, Syed A, Joachim N, Hong T, Broadhead G, Li H, Luo K, Chang A, Vision-related quality of life: 12 month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2016, [epub]

    Powner M, Sim D, Zhu M, Nobre-Cardoso J, Jones R, Syed A, Chang A , Keane P, Tufail A, Egan C. Evaluation of non-perfused retinal vessels in ischemic retinopathy. IOVS 2016, 1:57 (11) 5031-5037

    Bahrami B, Zhu M, Hong T, Chang A. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia 2016, 59(8): 1594-608

    G K Broadhead, JR Grigg, P McCluskey, M Korsakova, AA Chang. Bevacizumab for choroidal neovascularisation in enhanced S-cone syndrome. Documenta Ophthalmologica 2016; 133(2): 139-143

    Chang A, Broadhead G, Hong T, Joachim N, Syed A, Schlub T, Toth L, Peto T, Zhu M. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes. Opthalmic Research 2016; 55: 84-9

    Ewe S, Jamieson R, Chang A. Masquerade macular exudation in Mallatia Leventinese. Can J Ophthalmol 2016; 51: e24–e27

    2015

    Chang A, Li H, Broadhead G, Luo K, Zhu M, Safety and Efficacy of Intravitreal Preservative-free Triamcinolone Acetonide (Triesence) for Macular Edema. Journal of Ocular Pharmacology and Therapeutics. 2015:31(9):563-9

    Chang AA, Hong T, Ewe S, Badami B. The Role of Aflibercept in the management of Diabetic Macular Edema. Drug Design, Development and Therapy. 2015, 6:9:4389-96

    Broadhead GK, Chang AA. Intravitreal aflibercept for choroidal neovascularization complicating chronic central serous retinopathy. Graefes Archive for clinical and experimental ophthalmology.

    Broadhead GK, Grigg J, Chang AA, McCluskey P. Dietary Modification and Supplementation for the Treatment of Age-Related Macular Degeneration. Nutrition Reviews 2014.

    Staffieri SE, Rose L, Chang A, De Roach JN, McLaren TL, Mackey DA, Hewitt AW, Lamey TM. Clinical and molecular characterisation of females affected by X-linked retinoschisis. Clinical Experimental Ophthalmology 2015, 43(7):643-7

    Broadhead GK, T Hong, Zhu M, Schulb T, Wijeyakumar W, Chang AA. Response of Pigment Epithelial Detachments to Intravitreal Aflibercept among Patients with Treatment-Resistant Neovascular Age-Related Macular Degeneration. Retina, 2015; 35(5): 975-81

    2014

    Broadhead GK, T Hong, Zhu M, Schulb T, Wijeyakumar W, Chang AA. Response of Pigment Epithelial Detachments to Intravitreal Aflibercept Among Patients with Treatment-Resistant Neovascular Age-Related Macular Degeneration. Retina, 2014.

    Zhu M, Chew J, Broadhead G, Luo K, Joachim N, Hong T, Syed A, Chang AA. Intravitreal Ranibizumab for neovascular age-related macular degeneration in clinical practice: 5 year treatment outcomes. Graefes Archive for clinical and experimental ophthalmology, 2014.

    Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, Zhu M. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-related macular degeneration. Ophthalmology, 2014, 121(1): 188-192.

    Broadhead G and Chang AA. Acetazolamide for Cystoid Macular Oedema in Bietti Crystalline Retinal Dystrophy. Korean J Ophthalmol 2014;28(2):189-191.

    Broadhead G, Hong T, Chang AA. Treating the Untreatable Patient: Current Options for the Management of Treatment-Resistant Neovascular Age-Related Macular Degeneration. Acta Ophthalmologica 2014; 92(8):713-23.

    Vote B, Chang A, Bourke R. Intravitreal injections: a review of the evidence for best practice: Comment. Letter to the editor. Clinical and Experimental Ophthalmology. 2014; 42(1) p 96-98.

    Broadhead G, Grigg J, Chang A, McCluskey P. Efficacy and Safety of Saffron Supplementation: Current Clinical Findings. Critical Reviews in Food Science and Nutrition.

    Rush R, Simunovic M, Sheth S, Chang A Hunyor A. 23-Gauge Pars Plana Vitrectomy Versus Scleral Buckling Versus Combined Pars Plana Vitrectomy–Scleral Buckling for Medium-Complexity Retinal Detachment Repair. Asia-Pacific Journal of Ophthalmology: July/August 2014 – Volume 3 – Issue 4 – p 215-219

    Chang A. Retina tear and detachment. The need for early diagnosis. Medicine Today January 2014, volume 15, number 1.

     

    2013

    Chui J, Herkes G, Chang A. Management of fingolimod associated macular edema, JAMA Ophthalmology. 2013. 131(5) p 694-6

    Broadhead G and Chang A. Choroidal Neovascularisation in Acquired Partial Lipodystrophy. European journal Ophthalmology 2013; 23(3): p. 439-41

    Wang YD and Chang A. Clinical features and PDT effect of patients with CCSC. International Eye Science. 13:3. 522-526 January 2013

    Chang A. Editorial. Is there one less hurdle for patients undergoing macular hole surgery? Asia-Pacific Journal of Ophthalmology. 2(1):1-2, February 2013.

     

    2012

    Broadhead, GK, Chang, AA, and McCluskey, P, Genetics in Age-Related Macular Degeneration: Current Research and Implications for Future Treatment, Asia Pacific Journal Ophthalmology, 2012; 1(5): p. 312-18